Clinical Trials Directory

Trials / Completed

CompletedNCT03072576

Accuracy and Feasibility of Xpert Ultra

A Multicentre Study of the Diagnostic Accuracy and Feasibility of the Xpert Ultra for Detection of TB and Rifampin Resistance in Adults Suspected of Having Pulmonary TB

Status
Completed
Phase
Study type
Observational
Enrollment
1,400 (actual)
Sponsor
Foundation for Innovative New Diagnostics, Switzerland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.

Conditions

Interventions

TypeNameDescription
DEVICEXpert MTB/RIF UltraNext generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin

Timeline

Start date
2016-03-01
Primary completion
2017-03-01
Completion
2017-10-01
First posted
2017-03-07
Last updated
2018-02-08

Locations

6 sites across 4 countries: Belarus, Georgia, India, South Africa

Source: ClinicalTrials.gov record NCT03072576. Inclusion in this directory is not an endorsement.